Dr. Thierry Jahan
Clinical Professor in Thoracic Oncology at University of California San Francisco
Dr. Thierry Jahan was a highly respected medical oncologist and university professor with a focus on pleural mesothelioma. He retired in June 2020 from practice and teaching at the University of California San Francisco Medical Center.
Pleural Mesothelioma (retired)
University of California San Francisco Medical Center
1600 Divisadero St., San Francisco, CA 94115
JUMP TO A TOPIC
More About Mesothelioma Specialist Dr. Thierry Jahan
Dr. Jahan worked at the Helen Diller Family Comprehensive Cancer Center. This institution is an affiliate of the University of California San Francisco (UCSF) Medical Center and UCSF School of Medicine. Dr. Jahan retired from thoracic oncology in June 2020.
Dr. Jahan was a medical oncologist and researcher. He had a clinical interest in pleural mesothelioma. He worked in the field of thoracic oncology for more than 20 years.
He was also the clinical professor in thoracic oncology at UCSF School of Medicine. Dr. Jahan started his career at UCSF with a fellowship in hematology/oncology. He finished the fellowship in 1994 and soon after joined as a staff member.
- Medical Degree from George Washington University, 1987
- Residency in Internal Medicine at Cedars‑Sinai Medical Center, 1990
- Fellowship in Internal Medicine at Cedars‑Sinai Medical Center, 1991
- Fellowship in Hematology and Oncology at UCSF, 1994
- Board‑certified in medical oncology
- Membership in the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer and Association of Northern California Oncologists
- Member of the Council of Master Clinicians at the UCSF Department of Medicine
- Recipient of the UCSF Medical House Staff Outstanding Teacher Award
- Recipient of the UCSF Friend of Palliative Care Service Award
New Program for Mesothelioma Treatment
Dr. Jahan co‑founded the UCSF Medical Center’s Thoracic Oncology Program more than two decades ago. The program includes care for pleural mesothelioma.
Dr. Jahan encouraged multimodal treatment for mesothelioma. This means patients receive multiple types of therapy, including chemotherapy. Surgery, chemotherapy and radiation are often put together for mesothelioma. Another option is using immunotherapy before or after surgery.
He also recommended palliative options for late‑stage cases. Palliative therapy focuses on relieving symptom discomfort, such as fluid buildup and chest pain.
Leader in Clinical Research
Dr. Jahan has authored or co‑authored numerous peer‑reviewed medical articles. He also was a lecturer for national and international conferences on lung cancer and mesothelioma. He’s a member of the International Association for the Study of Lung Cancer, which has a conference each year.
As the principal investigator for many clinical trials focused on thoracic oncology, Dr. Jahan left a considerable mark on research of mesothelioma. Although his experience is varied, Dr. Jahan had a specific interest in testing target therapies. These include immunotherapy drugs, such as immune checkpoint inhibitors, and virotherapy agents. Opdivo and Yervoy for mesothelioma are examples of targeted therapies.
In 2016, Dr. Jahan became a member of the Council of Master Clinicians. He was inducted into the group, which is part of the UCSF Department of Medicine. The group is for outstanding doctors with exceptional knowledge, teaching skills and patient care.
Sources & Author
- Thierry Marie Jahan, M.D. University of California San Francisco. Retrieved from: https://top.ucsf.edu/meet-the-team/retired-faculty/thierry-marie-jahan-md.aspx. Accessed: 10/18/18.